NCT00008424已完成1 期
A Phase I Study of Irinotecan in Patients With Refractory Solid Tumors Who Are Concomitantly Receiving Anticonvulsants
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 51
- 主要终点
- Maximum tolerable dose (MTD) of irinotecan
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children with refractory or advanced solid tumors who are receiving anticonvulsants.
详细描述
OBJECTIVES:
- Determine the maximum tolerated dose of irinotecan in children with refractory or advanced solid tumors receiving anticonvulsants.
- Determine the dose-limiting toxicity of irinotecan in this patient population.
- Evaluate the pharmacokinetic behavior of this treatment regimen in these patients.
- Determine, preliminarily, the antitumor activity of this treatment regimen in these patients.
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to type of concurrent anticonvulsant (enzyme activating anticonvulsants vs valproic acid vs other anticonvulsants).
Patients receive irinotecan IV over 1 hour daily for 5 days. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed malignancy refractory to conventional therapy or for which no conventional therapy exists
- •Histologic confirmation not required for brain stem tumors
- •Concurrently on anticonvulsants at a steady level for at least 2 weeks
- •PATIENT CHARACTERISTICS:
- •1-21 years old
- •Performance status:
- •Karnofsky 50-100% (over 10 years of age)
- •Lansky 50-100% (10 years of age or under)
- •Life expectancy:
- •At least 8 weeks
- •Hematopoietic:
- •Neutrophil count at least 1,000/mm3
- •Platelet count at least 100,000/mm3 (transfusion independent)
- •Hemoglobin at least 8.0 g/dL (red blood cell transfusions allowed)
- •Bilirubin no greater than 1.5 times normal for age
- •SGPT less than 5 times normal for age
- •Albumin at least 2 g/dL
- •Creatinine no greater than 1.5 times normal for age OR
- •Creatinine clearance or radioisotope glomerular filtration rate at least lower limit of normal for age
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No uncontrolled infection
- •No evidence of active graft-vs-host disease
- •Neurologic deficits for CNS tumors stable for at least 2 weeks prior to study
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •At least 1 week since prior antineoplastic biologic therapy
- •At least 6 months since prior allogeneic stem cell transplantation
- •At least 1 week since prior growth factors
- •No concurrent sargramostim (GM-CSF)
- •No concurrent prophylactic growth factors during first course of study therapy
- •Recovered from prior immunotherapy
- •Chemotherapy:
- •At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosourea) and recovered
- •Endocrine therapy:
- •Concurrent dexamethasone for CNS tumors with increased intracranial pressure allowed if dose stable or decreasing for at least 2 weeks prior to study
- •Radiotherapy:
- •At least 2 weeks since prior local palliative radiotherapy (small part)
- •At least 6 months since prior craniospinal radiotherapy
- •At least 6 months since prior radiotherapy to at least 50% of pelvis
- •At least 6 weeks since prior substantial bone marrow radiotherapy
- •Recovered from prior radiotherapy
- •Not specified
- •No other concurrent investigational agent
排除标准
- 未提供
结局指标
主要结局
Maximum tolerable dose (MTD) of irinotecan
次要结局
未报告次要终点
研究者
研究点 (51)
Loading locations...
相似试验
已完成
2 期
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's LymphomaLymphomaNCT00003245M.D. Anderson Cancer Center50
已完成
1 期
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the PelvisSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaNCT00003368National Cancer Institute (NCI)
已完成
1 期
Irinotecan in Treating Patients With Progressive or Recurrent Malignant GliomaBrain and Central Nervous System TumorsNCT00003616Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
已完成
1 期
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00002939University of Chicago21
已完成
2 期
Irinotecan in Treating Patients With Advanced Neuroendocrine TumorsCarcinoma of Unknown PrimaryNeuroendocrine CarcinomaNeuroendocrine Carcinoma of the SkinNCT00004922Memorial Sloan Kettering Cancer Center